Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A gene by Maiti, Guru Prasad et al.
Overexpression of EGFR in Head and Neck Squamous
Cell Carcinoma Is Associated with Inactivation of SH3GL2
and CDC25A Genes
Guru Prasad Maiti1, Pinaki Mondal2, Nupur Mukherjee1, Amlan Ghosh1,3, Susmita Ghosh1,4, Sanjib Dey2,
Jayanta Chakrabarty5, Anup Roy6, Jaydip Biswas5, Susanta Roychoudhury2, Chinmay Kumar Panda1*
1Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India, 2Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of
Chemical Biology, Kolkata, India, 3Department of Zoology, Presidency University, Kolkata, India, 4Department of Pathology, Johns Hopkins School of Medicine, Baltimore,
Maryland, United States of America, 5Department of Surgical Oncology, Chittaranjan National Cancer Institute, Kolkata, India, 6North Bengal Medical College, Sushruta
Nagar,Darjeeling, West Bengal, India
Abstract
The aim of this study is to understand the mechanism of EGFR overexpression in head and neck squamous cell carcinoma
(HNSCC). For this reason, expression/mutation of EGFR were analyzed in 30 dysplastic head and neck lesions and 148 HNSCC
samples of Indian patients along with 3 HNSCC cell lines. In addition, deletion/methylation/mutation/expression of SH3GL2
(associated with EGFR degradation) and CDC25A (associated with dephosphorylation of EGFR) were analyzed in the same set
of samples. Our study revealed high frequency of EGFR overexpression (66–84%), low frequency of gene amplification (10–
32.5%) and absence of functional mutation in the dysplastic lesions and HNSCC samples. No correlation was found between
protein overexpression and mRNA expression/gene amplification status of EGFR. On the other hand, frequent alterations
(deletion/methylation) of SH3GL2 (63–77%) and CDC25A (37–64%) were seen in the dysplastic and HNSCC samples. Two
novel single nucleotide polymorphism (SNPs) were found in the promoter region of SH3GL2. Reduced expression of these
genes showed concordance with their alterations. Overexpression of EGFR and p-EGFR were significantly associated with
reduced expression and alterations of SH3GL2 and CDC25A respectively. In-vitro demethylation experiment by 5-aza-29-
deoxycytidine (5-aza-dC) showed upregulation of SH3GL2 and CDC25A and downregulation of EGFR expression in Hep2 cell
line. Poor patient outcome was predicted in the cases with alterations of SH3GL2 and CDC25A in presence of human
papilloma virus (HPV) infection. Also, low SH3GL2 and high EGFR expression was a predictor of poor patient survival. Thus,
our data suggests that overexpression of EGFR due to its reduced degradation and dephosphorylation is needed for
development of HNSCC.
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Introduction
Head and neck squamous cell carcinoma is the sixth most
common cancer worldwide and it accounts for 30–40% of all
cancer types in the Indian subcontinent [1]. Epidemiological
studies have linked tobacco, betel-nut leaf quid, alcohol and
infection with oncogenic type of HPV16/18 to the development of
HNSCC [1]. In the progression model of HNSCC, number of
alterations like overexpression of epidermal growth factor receptor
(EGFR) protein, deletion in chromosome 9p21, p16/p14 inactiva-
tion, trisomy of chromosome 7 and telomerase activation were
suggested to be associated with the development of hyperplastic
lesions of head and neck [2]. Among these alterations, overex-
pression of EGFR is quite important due to its regulation of
multiple cell signaling cascades. Nowadays, multiple therapeutic
targets have been made against EGFR to treat this tumor, but
success is still far behind [3].
Though, frequent (80–90%) overexpression of EGFR protein
was seen in HNSCC yet amplification of this locus was not
prevalent (10–30%) [4]. Even hemizygous of this locus showed
overexpression of this protein [5,6]. In addition, 1–7% of the
tumor showed mutation of this gene [4]. This suggests that other
mechanisms may be associated with the overexpression of EGFR in
HNSCC. It was evident that binding of EGF to EGFR triggered a
series of biochemical events including autophosphorylation of
specific tyrosine residues (like Tyr 1045, Tyr 992, Tyr 975, Tyr
1068, Tyr 1173 etc) in its kinase domain [4] i.e activated EGFR
protein level will be elevated without changing total EGFR protein
level [7,8]. The phosphorylation of Tyr-1045 is important as Cbl,
an E3 ubiquitin ligase, interacts at this site for initiation of its
endocytosis mechanism through CIN85-SH3GL2 interaction [9].
Frequent deletion (29–37%), promoter hypermethylation (42–
46%) and reduced expression (68%) of SH3GL2 (located at
chromosome 9p22.2) have been reported in head and lesions [1].
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Its reduced expression has also been seen in laryngeal carcinoma
[10]. It has mainly two domains. The SH3 domain of SH3GL2
interacts with CIN85, whereas the LPAAT domain of SH3GL2 is
associated with lysophophatydic acid acyl tyransferase activity
which converts lysophosphotidic acid (LPA) into phosphatidic acid
(PA) needed for membrane curvature for encapsulation of EGFR
[9]. However, to the best of our knowledge, association of SH3GL2
and EGFR in HNSCC has not yet been studied. On the other
hand, Shang, et al [11] reported that CDC25A, a dual phospha-
tase, could regulate the activity of EGFR through dephosphory-
lation of the tyrosine residues. Its frequent deletion (53%) and
reduced expression (64%) have been reported in HNSCC [1].
However, like SH3GL2, association of CDC25A with EGFR in
HNSCC has not yet been studied.
Thus, to understand the molecular mechanism of EGFR protein
overexpression, we analyze the alterations of EGFR, SH3GL2 and
CDC25A in the same set of HNSCC samples. At first, alterations
(expression, gene amplification and mutation) of EGFR were
analyzed in primary head and neck lesions of Indian patients and
some HNSCC cell lines. Then, alterations (deletion/promoter
methylation/mutation/expression) of SH3GL2 and CDC25A were
analyzed in these samples. Our data suggests that overexpression
of EGFR protein might be due to the impairment of the SH3GL2
associated endocytosis mechanism, whereas down regulation of
CDC25A in this tumor might lead to the EGFR protein in its active
state.
Materials and Methods
Ethics Statement
The Institutional Ethical board of Chittaranjan National
Cancer Institute, Kolkata approved the usage of Human
specimens in this study. The above board approved usage of
these human clinical samples specifically in this study, related to
the involvement of the study of EGFR homeostasis in HNSCC.
The tumor specimens were collected from the hospital section of
Chittaranjan National Cancer Institute, Kolkata, after obtaining
written, informed consent of the concerned patients, in stipulated
format, approved by the above mentioned Institutional Ethical
board of Chittaranjan National Cancer Institute, Kolkata, India.
Blood samples were collected from healthy control with written
informed consent as approved by the Institutional ethical Board.
Patient Population, Tumor Tissues and Cell Lines
Total 178 tumor tissue samples of head and neck lesions as
well as matched adjacent normal tissues were collected from
Chittaranjan National Cancer Institute, Kolkata, India. The
primary tumors were collected from patients after surgical
resection having no previous treatment record. All these tumors
were graded and staged according to UICC TNM classification.
Samples were frozen immediately after collection at -80uC until
use. Part of the freshly operated tissues was directly collected in
TRIzol reagent (Invitrogen, San Diego, CA) for RNA isolation
and another part was fixed in formalin and embedded in
paraffin for immunohistochemical analysis. Clinicopathological
information of the patients (n = 178) were presented in Table 1
and unrelated control (n = 52) having no previous and present
history of HNSCC was presented in Table S1. Among HNSCC
cell lines Hep2 and KB were procured from the National
Centre for Cell Sciences, Pune, India and UPCI: SCC 084 was
kindly provided by Prof. Susanne M. Gollin, University of
Pittsburgh, PA. Summary of the total samples usage used in
different experiment was shown in Figure 1.
Microdissection and DNA Extraction
The contaminant normal cells in the head and neck lesions were
removed by microdissection procedure from cryosections (5 mm)
using surgical knives under a dissecting microscope (Leica MZ16,
Germany). The representative sections from different regions of
the specimens were stained with hematoxylin and eosin for
diagnosis as well as for marking of the dysplastic epithelium/tumor
rich regions. The samples containing .60% dysplastic epitheli-
um/tumor cells were taken for isolation of DNA according to the
standard procedure [12]. High-molecular-weight DNA was
extracted by proteinase-K digestion, followed by phenol/chloro-
form extraction [13].
Immunohistochemical (IHC)/Immunocytochemical (ICC)
Analysis
The protein expression of EGFR, SH3GL2 and CDC25A was
done by immunohistochemical analysis in 50 primary tumor
samples and by immunoflorescence analysis in Hep2, KB,
SCC084 according to the standard procedure as describe earlier
[14]. The tissues were reacted overnight with primary antibodies
CDC25A (sc-6947), SH3GL2 (sc-10874), EGFR (sc-03) and p-EGFR
(sc-57541) at a dilution of 1:80 at 4uC. HRP conjugated rabbit
anti-goat (sc-2020), goat anti rabbit (sc-2004) and goat anti mouse
(sc-2005) secondary antibody was added 1:500 dilutions. The slides
were developed using 3–39 diaminobenzidine (DAB) as the
chromogen and counterstained with hematoxylin and photo-
graphed in Bright Field microscope (Leica DM1000, Germany).
The staining intensity (1 =weak, 2=moderate, 3 = strong) and the
percentage of positive cells (,1= 0, 1–20= 1, 20–50= 2, 50–
80= 3 and .80= 4) were detected by 2 observers independently
and by combining the two scores, final evaluation of expression
was done (0–2= low, 3–4= intermediate, 5–7= high) [6].
For immunofluroscence analysis, cover slip culture of Hep2, KB
and SCC 084 cell lines were reacted with the same dilution of
primary antibody of these genes after permeabilisation with 0.5%
Triton X-100 and blocking with 5% BSA. After washing, the
coverslips were incubated with FITC conjugated corresponding
secondary antibody goat anti mouse (sc-2010), goat anti rabbit (sc-
2012) and rabbit anti goat (sc-2777) at 1:500 dilution and mounted
with glycerol after thorough washing. Imaging of the cover slip was
performed in florescence microscope (Leica DM4000 B, Ger-
many).
Quantification of EGFR Gene Copy Numbers
A quantitative measurement of EGFR amplification was carried
out using differential polymerase chain reaction (DPCR) method
[15] using the primer as shown in Table S2. The primer from
exon-20 of EGFR gene was selected for amplification analysis. The
dopamine D2 receptor gene (DRD2) gene was used as internal
control due to low frequency of alterations reported in HNSCC
[15]. The gene amplification by DPCR method is validated by
real-time quantitation. See Supplementary method for details of
the protocol (Doc S1).
Mutation Analysis
The mutation of EGFR and SH3GL2 was screened in 30
dysplastic lesions, 148 invasive samples and 3 oral cancer cell
lines by single strand conformation polymorphism (SSCP)
analysis using [a-P32] dCTP as described by Tripathi el al
[16].The mutational hotspot region of kinase domain encom-
passing the exon-18 to exon-21 were selected for mutation
analysis of EGFR. For mutation analysis of SH3GL2, important
enzymatic domain and alternating splice site of the gene were
Overexpression of EGFR in HNSCC
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e63440
selected. Exon 9 & exon-10 encoded the SH3domain and exon-
1 & exon-2 encoded the lysophosphatydic acid acyl transferase
enzymatic domain of the gene. The alternating splice sites were
located in exons 3, 4, &5. All these exons were selected for
mutation analysis of SH3GL2. Primer sequences and locations
were presented in Table S2 & Figure S2b, A.4a. Electrophoresis
was done in 6% nondenaturing polyacrylamide gel with 10%
glycerol at 2 W for overnight and autoradiographed on X-ray
film (Kodak, USA). Sequencing of both strands of samples
showing abnormal band shift was done using 3130xl-Genetic
Analyzer (Applied Biosystems, USA).
Deletion Analysis of SH3GL2 and CDC25A
In microsatellite based deletion mapping, a standard polymer-
ase chain reaction (PCR) containing [c-P32] ATP end labeled
forward primer was done in a 20 ml reaction volume according
standard procedure as describe earlier [14]. The microsatellite
markers are selected on the basis of their map positions and
heterozygosity (http://www.ensembl.org, Release-49). An intra-
genic microsatellite marker D9S157 located 17.61 Mb from p-ter
of chr. 9 was taken for analysis of SH3GL2 and D3S3560 locus
located 48.16 Mb from p-ter of chr. 3 and 4.8 Kb telomeric of the
gene was taken for deletion analysis of CDC25A. Details of the
markers was shown in Table S3.
Promoter Methylation Analysis
The promoter methylation of the candidate genes SH3GL2 and
CDC25A was analyzed by PCR-based methylation sensitive
restriction analysis (MSRA) method using MspI/HpaII restriction
enzymes (Sibenzyme, Russia) using standard procedure as describe
previously [14]. Details of primer sequences are listed in Table S2.
The methylation data obtained by MSRA was validated by
methylation-specific PCR (MSP) according to standard procedure
[17]. See Supplementary method for details of the protocol (Doc
S1).
mRNA Expression Analysis
mRNA expression of SH3GL2, CDC25A and EGFR were
analyzed in 22 primary HNSCC samples and their corresponding
normal head and neck tissues and 3 cell lines (Hep2, KB and SCC
084) using primers as mentioned in Table S2. Total RNA was
isolated from samples using TRIzol reagent according to the
manufacturer’s protocol (Invitrogen). Reverse transcription was
performed with 1 mg total RNA using Random hexamer
(Invitrogen) and M-MuLV-Reverse Transcriptase (Promega,
USA). Relative expression of the gene was measured by Real-
Time quantitation method as described previously [14]. b2-
microglobulin (B2M) was used as a internal control.
Cell Lines and 5-aza-dC Treatment
In our previous analysis of 5-aza-dc experiment at different
concentrations (5–50 mM) it was evident that the cell viability was
unaltered up to 5 days of 5-aza-dc treatment at 20 mM
concentration. For this reason, the 5-aza-dc concentration was
taken upto 20 mM in Hep2 cell line. Subconfluent cultures of
Hep2 was treated with 5 mM, 10 mM and 20 mM demethylating
agent, 5-aza-dC (Sigma, USA) for 5 days. Controls without 5-aza-
dC were cultured concomitantly in the same manner. After
completion of treatment, cells are harvested and proceeded for
next experiment.
For kinetic study, subconfluent cultures of Hep2 cell line were
treated with 20 mm 5-aza-dc in six Petri dish and the cells were
harvested at different time point like 0 hour, 24 hours, 48
hours, 72 hours, 96 hours and 120 hours after aza treatment
and protein was isolated from the cells. For immunoflorescence
analysis after aza treatment, Hep2 cells were grown over night
on cover slip and treated with 20 mm 5-aza-dc for 72 hour.
Then the cells were fixed with chilled methanol and used for
immunoflorescence analysis.
Gene Knock Down by siRNA Treatment
The siRNA mediated knock down of SH3GL2 and CDC25A
experiment was done in oral cancer cell line SCC084 according to
Figure 1. Tumor samples usage. Schematic representation of the usage of primary HNSCC tumor in different experimental analyses. N,sample
number; HNSCC, head and neck squamous cell carcinoma; IHC, Immunohistochemical analysis; AMP, Gene amplification analysis; Del, deletion
analysis; MSRA, Methylation Sensitive Restriction Analysis; Mut, Mutation analysis by SSCP; QRT-PCR, Real time-PCR quantification.
doi:10.1371/journal.pone.0063440.g001
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standard procedure [18]. Briefly, about 26105 cells were plated in
35 mm petri dish. After 24 hour, media was replaced with serum
and antibiotic free media and siRNAs were transfected using
Lipofectamin 2000 (Invitrogen) according to the manufacturer
protocol. The siRNA of SH3GL2 (SC-35304), CDC25A (SC-
29254) and scrambled control (SC-37007) were purchased from
Santa Cruz Biotechnology, CA, USA and were used at a final
concentration of 80 pmole. After siRNA transfection, cells were
harvested at different time point like 24 hour, 48 hour, 72 hour
and 96 hour for each gene and RNAs were isolated to find out the
time point for maximum gene knock down by real time
quantitation. After characterizing the time for optimum gene
knock down, cells were again treated with siRNA and harvested
after particular time to isolate the protein.
Western Blot Analysis
Proteins were extracted from cells by using standard protocol
[19] and transferred to PVDF membrane after gel electrophoresis.
The PVDF membrane was incubated with primary antibody for
EGFR, p-EGFR(sc-12351), SH3GL2, CDC25A, Actin (sc-8432) and
alpha-tubulin (sc-5286) and HRP-tagged secondary antibodies and
developed with luminol (sc-2048; Santa Cruz Biotechnology,
USA). The signal intensities were scanned by densitometric
scanning (Bio-Rad GS-800). The same membrane was used for
incubation with different antibodies after stripping with 0.2M
NaOH (See Supplementary method for details of the protocol Doc
S1).
Detection of HPV-16 and HPV-18
Presence of HPV in the head and neck lesions was detected by
PCR using primers (MY09 and MY11) from the consensus L1
region followed by typing of HPV 16/18 in the L1 positive
samples as described previously [14].
Statistical Analysis
Fisher’s exact test was used to determine the association
between tumors genetic profile and different clinicopathological
features. All statistical tests were 2-sided and considered significant
at probability value, p,0.05. Survival curves were calculated
according to Kaplan–Meier method in 148 HNSCC samples. For
this method, p values were evaluated by the log rank test for
censored survival data. A Cox-proportional hazards regression
model was used to test the statistical significance of several
potential prognostic factors like clinical stage, tumor site, tobacco
exposure, HPV infection and alterations of the candidate TSGs
that were jointly predictive of overall survival of the patients. From
this model we estimated the hazard ratio (HR) for each potential
prognostic factor with a 95% confidence interval (CI) in univariate
and a multivariate fashion. All the statistical analysis was
performed using statistical programs Epi Info 6.04 b, SPSS 9.0
(SPSS, Chicago, IL).
Bioinformatics Analysis
All the oligonucleotides primers used in different experiment
were designed using primer-3 software [20]. Transcription factor
binding site of SH3GL2 promoter was analyzed uising on line
server Alibaba 2.1 TF Binding Prediction software [21].
Results
Molecular Alterations of EGFR
Immunohistochemical/immunocytochemical
analysis. In normal oral epithelium, high cytoplasmic as well as
membrane bound expression of EGFR was seen in basal layer
followed by gradual decrease in parabasal and spinous layers
(Figure 2a). In premalignant oral lesions, high cytoplasmic as well
as membrane bound expression of EGFR was seen in basal,
parabasal and part of the spinous layer in 66% (4/6) of dysplastic
lesions. In invasive HNSCC tumor, overexpression of EGFR was
observed in 84% (37/44) samples irrespective of tumor stages
(Figure 2a). In immunocytochemical analysis of HNSCC cell lines,
high expression of EGFR was seen in the following order: Hep2.
KB.SCC084 (Figure S3). This indicates that high expression of
EGFR is needed for development of dysplastic lesions and
subsequent stages of HNSCC.
Table 1. Clinicopathological feature of head and neck lesions.
Clinical No of samples
HPV 16/18
positivity
Features (n=178) (n%) + (n %) 2 (n %) p-value
Age 54.8611.2 93(52.2) 85(47.8)
(Mean6SD)
Mean $54.8 84(47.2) 41(48.8) 43(51.2) 0.385
Mean #54.8 94(52.8) 52(55.5) 42(44.5)
Primary sites
BM 96(53.9) 51(53.1) 45(46.8) 0.156
ALV 35(19.6) 10(28.6) 25(71.4)
TNG 27(15.1) 16(59.3) 11(40.7)
Others # 20(11.2) 15(75) 5(25)
Sex
Male 132(74.2) 68(51.5) 64(48.4) 0.741
Female 46(25.8) 25(54.4) 21(45.6)
Tumor stage
Dysplasia 30(16.8) 14(46.6) 16 (53.3)
TNM stage I 18(10.1) 5(27.8) 13(72.2)
TNM stage II 42(23.5) 27(64.3) 15(35.7) 0.214
TNM stage III 48(26.9) 27(56.25) 21(43.75)
TNM stage IV 40(22.4) 22(55) 18(45)
Tumor
Differentiation$
WDSCC 84(47.2) 45(53.6) 39(46.4)
MDSCC 55(30.8) 32(58.2) 23(41.8)
PDSCC 9(5) 4(44.4) 5(55.6) 0.989
Lymph node$
Positive 42 (23.5) 25(59.5) 17(40.5) 0.462
Negative 106 (59.5) 56(52.8) 50(47.2)
Tobacco
Tobacco + 129 (72.4) 73(56.5) 56(43.4) 0.0341*
Tobacco 2 49(27.5) 19(38.7) 30(61.2)
$
Excluding dysplasia,
#Samples including thyroid, nasopharyngs, larynx,
*Statistically significant.
Abbreviation: HPV, Human papiloma virus; SD, Standard deviation; BM,
buccal mucosa; ALV, alveolus; TNG, tongue; TNM, tumor-node-metastasis;
WDSCC, well differentiated squamous cell carcinoma; MDSCC, moderately
differentiated squamous cell carcinoma; PDSCC poorly differentiated squamous
cell carcinoma.
doi:10.1371/journal.pone.0063440.t001
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Gene amplification analysis. In DPCR analysis, about
26.4% (47/178) of the head and neck lesions showed EGFR
amplification (Figure 2b). Gradual increase in amplification has
been seen from dysplasia (10%, 3/30) to invasive lesions (31%, 46/
148) (Figure S1a). No amplification was found in the HNSCC cell
lines. The DPCR analysis showed concordance (p = 0.0007) with
gene amplification analysis through real time PCR method (Table
S4). Thus, EGFR overexpression through gene amplification might
not be the sole mechanism.
Mutation analysis. In SSCP analysis, about 13% (24/178)
and 20% (35/178) of the HNSCC samples showed altered bands
in exon-18 and exon-20 respectively (Table S5a & Figure S1b, c,
d). No altered band was observed in exon-19 and exon-21. Also,
no altered band was found in the three cell lines. In sequencing
analysis of the samples having altered bands it was evident that a
SNP (G.A: rs17337107) in the down stream of exon-18 i.e.
intron-18 and a SNP (G.A: rs1050171) at codon 787 in exon- 20
were located (Figure S1b, e & Table S5c). However, 12/24 of
tumor samples showed A.G transition mutation in the SNP
(G.A: rs1050171) (Table S5b). Thus, functional mutation in
EGFR is a rare event in HNSCC.
mRNA expression analysis. It was revealed that 12% (3/
25) of the HNSCC samples showed overexpression of EGFR
mRNA with mean fold expression of 1.46 (610.58) (Figure 2c).
The mRNA expression showed concordance with gene amplifi-
cation (p= 0.0025), while no correlation between mRNA expres-
sion and protein expression was observed (p = 0.5528) (Table 2).
No overexpression was seen in the three HNSCC cell lines. This
suggests that overexpression of EGFR protein is not associated with
its mRNA expression.
Molecular Alterations of SH3GL2 and CDC25A
Deletion analysis. After excluding non-informative tumor
samples (21 of 178 at SH3GL2 and 60 of 178 at CDC25A locus),
high frequency of deletion was observed in SH3GL2 (34%, 54/
157) and CDC25A (52%, 56/108) loci (Figure 3a, b). The deletion
frequencies in SH3GL2 and CDC25A were observed in 27% (7/26)
and 37% (6/16) dysplastic lesions respectively. Comparable
frequency of SH3GL2 deletion (30–46%) was observed in
subsequent stages, while deletion frequencies of CDC25A (37–
41%) were comparable upto stage-I/II followed by significant
increase (61–64%) in stage-III/IV of the HNSCC samples
(Figure 3f, Figure S4). In addition, MA was observed in both
SH3GL2 and CDC25A loci in varying frequencies (4–16%) (Figure
S4). This indicates that deletion might be one of the mechanisms
of inactivation of SH3GL2 and CDC25A in HNSCC, as reported in
our earlier studies [1,14]. A statistically significant correlation was
observed between SH3GL2 and CDC25A alterations (p = 0.05) in
tumor samples (Table S6).
Figure 2. Molecular alterations of EGFR in HNSCC. a) Immunohistochemical analysis of EGFR proteins in normal, dysplasia and HNSCC. Distinct
cytosolic/membrane expression of EGFR in the basal lining/parabasal cells/spinous cells of normal oral epithelium, dysplasia and HNSCC samples.
EGFR has high cytoplasmic expression in the basal cells followed by gradual decrease in parabasal and spinus layer of normal oral epithelium. #L50
(AMP+), #51T(AMP+) and #5999T(AMP-) showed overexpression of cytoplasmic and membrane EGFR. # 403 (AMP-) showed medium EGFR
expressions. Arrows point to membrane/cytoplasmic expression. Magnification of tissue samples is 206, and inset magnification is 406. Scale bars in
tissue sections represent 100 mm. AMP+/2, gene amplification present/absent. b) Representative gel diagram featuring amplification of EGFR locus.
DDR2 locus was used as the control locus. The sample number was indicated above the figure. Arrow head indicate the amplified band in #3371T. T:
Tumor DNA, N: corresponding normal DNA. c) Quantitative RT-PCR showing mRNA expression pattern of EGFR in HNSCC samples and cell lines. Bars
represent the gene expression normalized to b2-microglobulin and relative to corresponding adjacent normal tissues, using 2-ddCt method. The line
illustrates the mean fold of expression level. X-axis indicates the sample numbers.
doi:10.1371/journal.pone.0063440.g002
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Promoter methylation analysis. In MSRA, high frequency
(44%, 78/178) of promoter methylation was seen in the SH3GL2
gene in HNSCC lesions (Figure 3c). No promoter methylation of
CDC25A was observed in the samples as seen in our previous
report (Figure 3d) [14]. In the HNSCC cell lines, Hep2 showed
methylated promoter of SH3GL2, whereas no methylation was
detected in SCC084 and KB. The results were validated in
randomly chosen 30 HNSCC samples and 3 oral cancer cell lines
using MSP method after bisulfite modification of DNA (Figure 3e).
Concordance was seen between MSRA and MSP analysis
(p = 0.009) (Table 3). In dysplastic lesions 40% (12/30) of the
samples showed promoter methylation of SH3GL2 with compa-
rable frequency (43–46%) of methylation in subsequent stages of
HNSCC (Figure S4a). Thus it was evident that overall alterations
(deletion/methylation) of SH3GL2 was high (63%, 19/30) in
Table 2. Correlation of molecular alterations with RNA/protein expression of the genes SH3GL2 and CDC25A and the relationship
between the protein expression of EGFR vs SH3GL2 and CDC25A vs p-EGFR.
EGFR SH3GL2 CDC25A p-EGFR1045
Genetic Expression Genetic Expression Genetic Expression Expression
Altn RNA Protein Altn RNA Protein Altn RNA Protein Protein
Dysplastic lesions
L7 Amp2 ND ++ D2M2 ND +++ D2 ND ++ ++
L48 Amp2 ND +++ D2M+ ND ++ D2 ND +++ +
L50 Amp+ ND +++ D2M+ ND ++ D2 ND ++ ++
L52 Amp2 ND ++ D+M2 ND + D2 ND +++ ++
L58 Amp2 ND +++ D2M+ ND + D2 ND +++ +
L127 Amp2 ND +++ D+M+ ND + D+ ND + +++
HNSCC cell line
Hep2 Amp2 Normal +++ D2M+ Q + D2 Q ++ ++
SCC084 Amp2 Normal + D2M2 Normal +++ D2 Normal +++ ++
KB Amp2 Normal ++ D2M2 Normal +++ D2 Normal +++ ++
HNSCC samples
3689 Amp2 Normal ++ D2M+ Q ++ D2 Normal ++ ++
7077 Amp2 Normal +++ D2M+ QQ ++ D+ QQ + +++
2649 Amp2 Normal +++ D+M2 Q + D+ QQ + +++
4465 Amp2 Normal +++ D2M+ Q ++ D2 Normal +++ +
3371 Amp+ q +++ D2M+ Q ++ D2 Q +++ +
315 Amp2 Normal +++ D+M2 QQ + D2 Normal ++ ++
3187 Amp2 Normal +++ D+M+ QQ + D2 Normal +++ +
5999 Amp2 Normal +++ D+M2 Q + D+ QQ + +++
5314 Amp2 Normal ++ D2M+ QQ ++ D+ QQ + +++
91 Amp2 Normal +++ D2M+ Q ++ D2 Normal ++ ++
403 Amp2 Normal +++ D+M+ QQ ++ D2 Normal +++ +
3910 Amp2 Normal +++ D2M+ Q ++ D2 Q ++ ++
2496 Amp2 Normal +++ D+M+ QQ + D+ QQ + +++
4892 Amp+ q +++ D+M2 QQ + D2 Q ++ ++
2935 Amp2 Normal +++ D2M+ Q ++ D2 Q ++ ++
5232 Amp2 Normal +++ D+M+ QQ + D+ Q + +++
3484 Amp2 Normal +++ D+M+ QQ + D2 Normal +++ +
3489 Amp2 Normal +++ D2M+ Q ++ D2 Q ++ ++
51 Amp+ q +++ D+M+ QQ + D2 Normal ++ ++
4283 Amp2 Normal +++ D+M2 QQ + D+ QQ + +++
2333 Amp2 Normal ++ D2M2 Normal +++ D+ + +++
1416 Amp2 Normal +++ D+M2 QQ + D+ QQ + +++
p value 0.0025* 0.5528 0.00043* 0.00003* 0.0027* 0.011* 0.00005*
0.0011* 0.0117*
D+/2: Deletion (MA, LOH) positive/negative, M+/2: Methylation positive/negative,/: increased/decreased gene expression compared to normal. ND: Fresh tissues were
unavailable for RNA isolation, *: statistically significant (p,0.05).
doi:10.1371/journal.pone.0063440.t002
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Figure 3. Molecular alterations of SH3GL2 and CDC25A. a) Representative autoradiographs showing deletion and MA in HNSCC samples at
D9S157 marker loci. (i) LOH, loss of heterozygosity, (ii) MA-I, microsatellite size alteration of one allele, (iii) LMA microsatellite size alteration of of one
allele and LOH in other allele. b) Genetic alterations of CDC25A analyzed by microsatellite based deletion mapping showing deletion and MA in
HNSCC at D3S3560 marker loci (i) LOH loss of heterozygosity, (ii) MA-I microsatellite size alteration of one allele. (iii) MA2 microsatellite size alteration
of both alleles. Arrow heads indicate the lost allele and star indicates the allele with MA. Representative gel electrophorogram showing the
methylation status of c) SH3GL2 and d) CDC25A in tumor samples and in corresponding normal sample by MSRA. SH3GL2 showed methylation in
tumor sample and absence of methylation in adjacent normal samples. Promoter methylation of CDC25A was absent in both tumor and normal
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dysplastic lesions and became comparable (64%–77%) in subse-
quent stages of tumor progression (Figure 3f).
Mutation analysis of SH3GL2. In SSCP analysis, altered
bands in exon-1 were seen in 18% (32/178) HNSCC samples and
also in their respective normal samples (Figure S2b & Table S7a).
No other exons showed any altered band. In sequencing analysis
of the samples having altered bands in exon-1, two novel sequence
variations at231 (C.T) and 264 (G.T) flanked by two reported
SNPs (24 G.C, rs4961573; 286 C.G, rs11540996) were found
in 2/32 and 10/32 tumor and respective normal samples
respectively (Figure S2c).
To identify the nature of observed sequence variations,
sequencing analysis of these variants was done in 52 control
DNA samples. The 231 heterozygous allele variant (C.T) was
observed in 4% (2/52) control samples (Table S7b, c). On the
other hand, 8% (4/52) control samples were heterozygous with
G.T variation at 264 nucleotide position. This suggests the
presence of two novel SNPs in the 231 and 264 nucleotide
positions. Both the sequence variation was submitted in the gene
bank (accession no. rs112820965 & rs201266191). Interestingly,
the frequency of T allele at 264 G.T variation seems to be
higher (0.16) in HNSCC patients than the control population
(0.04), whereas no such preference has been seen in the C.T
variation in the 231 nucleotide position (Table S7b, c). A GC
Factor (GCF) transcription binding site was identified at 264
nucleotide position by Insilco analysis using Alibaba 2.1 TF
binding prediction online software (Figure S2d). However, large
number should be analyzed to find their association in HNSCC.
Thus, it suggests that mutation of SH3GL2 is a rare event in
HNSCC.
mRNA expression analysis of SH3GL2 and CDC25A. It
was evident that 80% (20/25) primary HNSCC samples showed
$2 fold reduction of SH3GL2 mRNA expression with 6.4
(613.5632) mean fold reduction (Figure 3g). In case of CDC25A
reduced expression was seen in 60% (15/25) of the samples with
2.4 (614.41543) mean fold reduction (Figure 3h). No change in
expression pattern of genes was seen in the cell lines except
reduced expression of SH3GL2 and CDC25A in Hep2. The
reduced expression of SH3GL2 and CDC25A in HNSCC showed
concordance with their genetic alterations (deletion/methylation)
(p = 0.00043; p= 0.00278) (Table 2).
Protein expression analysis of SH3GL2, CDC25A and p-
EGFR. Immunohistochemical analysis revealed a differential
expression pattern of SH3GL2, CDC25A and p-EGFR in the basal/
parabasal/spinous cells of normal oral epithelium (Figure 4a, b, c).
SH3GL2 showed a diffused low cytoplasmic expression in the
basal/parabasal cells and high cytoplasmic/membrane expression
in spinous cells of normal oral epithelium. Low and diffuse nuclear
and cytoplasmic expression of CDC25A was seen in basal and
parabasal layers of normal oral epithelium followed by high
nuclear expression in the spinous layers. Like EGFR, high nuclear
and cytoplasmic expression of p-EGFR seen in basal layer
gradually decreased in parabasal and spinus layers (Figure 4c). It
seems that reduced expression of SH3GL2 and CDC25A in normal
basal oral epithelium might lead to high expression of EGFR and
p-EGFR essential for maintenance of basal stem cell proliferation.
In primary tumors, reduced expression of SH3GL2 was evident
in 78% (39/50) of the samples (Figure 4b). Mainly cytoplasmic
expression of SH3GL2 was seen in KB and SCC084 with reduced
expression in Hep2 (Figure S3b, c, a). Concordance was seen
between reduced expression of SH3GL2 and its molecular
samples. h, amplicon obtained with primer for HpaII digested DNA; m, amplicon obtained with primer for MspI digested DNA; u, amplicon obtained
with primer for undigested DNA. e) The methylation analysis by MSRA was validated by MSP after bisulphate modification of DNA. The sample
#2123T showed the methylalaton specific PCR band, but #2123N and #2935TN showed unmethylation specific PCR band. U; amplicon obtained
with primer for modified unmethylated DNA, M amplicon obtained with primer for modified methylated DNA, T tumor DNA, N corresponding normal
tissue DNA. f) Frequency of overall alterations of the genes SH3GL2 and CDC25A observed in dysplasia and different stages of HNSCC samples.
Significant increase in alteration with tumor progression is shown by asterisk. Q-RT PCR showing reduced expression of g) SH3GL2 and h) CDC25A in
HNSCC tumor. Bars represented the gene expression normalized to b2-microglobulin and relative to adjacent normal tissues using the 2ˆ-ddCt method.
The line illustrates the mean decreased level of the genes. X-axis indicates samples.
doi:10.1371/journal.pone.0063440.g003
Table 3. Correlation of the two methods of promoter
methylation analysis.
Sample SH3GL2 Sample SH3GL2
4446 MSRA + 3187 MSRA +
MSP + MSP +
3371 MSRA + 4145 MSRA 2
MSP + MSP 2
315 MSRA 2 3484 MSRA +
MSP 2 MSP +
5314 MSRA + 363 MSRA 2
MSP + MSP 2
91 MSRA + 3689 MSRA +
MSP 2 MSP +
5138 MSRA + 206 MSRA 2
MSP + MSP 2
2935 MSRA 2 1108 MSRA +
MSP + MSP +
4892 MSRA 2 5314 MSRA +
MSP 2 MSP +
3910 MSRA + 2507 MSRA 2
MSP + MSP +
3127 MSRA 2 2323 MSRA +
MSP 2 MSP 2
2496 MSRA 2 410 MSRA +
MSP + MSP +
4283 MSRA 2 7216 MSRA +
MSP 2 MSP +
5232 MSRA + 558 MSRA 2
MSP + MSP 2
2649 MSRA 2 1332 MSRA +
MSP 2 MSP +
3006 MSRA 2 % of MSRA 57% (17/30)
MSP + methylation MSP 63% (19/30)
L50 MSRA + Significance p value 0.00009*
MSP + level
MSRA, methylation sensitive restriction enzyme assay; MSP, Methylation specific
PCR.;
*statistically significant; +, Methylation positive; 2, Methylation negative.
doi:10.1371/journal.pone.0063440.t003
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alterations in the samples (p = 0.00003) (Table 2). In addition,
reduced expression of SH3GL2 showed significant association
(p = 0.0011) with overexpression of EGFR in the samples (Table 2).
In the tumors, low or intermediate level of nuclear and
cytoplasmic expression of CDC25A was observed in 70% (35/50)
of the samples. Cytoplasmic and perinuclear expression of
CDC25A was seen in the cell lines with low expression in Hep2
(Figure S3a, b, c). The expression of CDC25A was concordant with
its deletion pattern of the samples (p = 0.011) (Table 2). In case of
p-EGFR, high/intermediate nuclear and cytoplasmic expression
was seen in 82% (41/50) of the samples (Figure 4c). Cytoplasmic
and nuclear expression of p-EGFR was seen in the cell lines (Figure
S3a, b, c). Interestingly, the high expression of p-EGFR in the
tumors showed correlation with reduced expression of CDC25A
(p = 0.0117 ) (Figure 4b, c and Table 2).
Validation of SH3GL2 and CDC25A Mediated EGFR
Regulation
To find out the SH3GL2 and CDC25A mediated regulation of
EGFR/p-EGFR demethylation experiment in presence of 5-aza-dc
was done in Hep2 cell line. It was evident that the mRNA
expression of SH3GL2 and CDC25A was gradually increased with
increasing concentration of 5-aza-dc with significant increase of
SH3GL2 at higher concentration (Figure S5). Interestingly, at
20 mM concentration of 5-aza-dc EGFR protein expression was
gradually decreased with significantly low after 48 hours of
treatment and became considerably low at 120 hours (Figure 5a,
b). On the other hand, SH3GL2 protein expression was
significantly increased after 48 hours of treatment and became
high at 120 hours. Similarly, gradual increase in CDC25A protein
expression was seen with time of treatment. In ICC analysis of
expression of these proteins in Hep2 after treatment with 20 mm 5-
aza-dc for 72 hours, high expression of SH3GL2 and CDC25A were
seen in nucleus and cytoplasm, whereas expression of both EGFR
and p-EGFR were considerably reduced (Figure 6). The percent of
increase or decrease of the proteins was shown in Table S8.
To confirm the SH3GL2 and CDC25A mediated regulation of
EGFR/p-EGFR, further siRNA mediated knockdown experi-
ments of SH3GL2 and CDC25A were performed in SCC084 cell
line. The mRNA expression of SH3GL2 and CDC25A was
Figure 4. Immunohistochemical analysis of SH3GL2, CDC25A and p-EGFR. a) Distinct cytoplasmic/membrane expression of SH3GL2 in the
basal lining/parabasal cells of normal oral epithelium and primary HNSCC samples were seen. Spinus layer showed high expression of the gene.
#403T and #5999T showed low expression, #4465T and #2333T showed intermediate/high expression expression level of SH3GL2. b) Differential
nuclear and cytoplasmic expression of CDC25A was seen in basal/parabasal/spinus layer cells of normal oral epithelium and tumor samples. Low
cytoplasmic and nuclear expression of CDC25A was evident in basal and parabasal cells of normal epithelium, but higher expression in spinus layer.
#2333T and #5999T showed low expression, #4465T and #403T showed high/intermediate nuclear and cytoplasmic expression level of CDC25A.
Arrows pointed to nuclear/cytoplasmic/membrane expression. c) Distinct cytoplasmic and membrane bound expression of p-EGFR was seen in
normal oral epithelium. The expression was high in basal layer but gradually decreased in parabasal and spinus layer. Arrows pointed to cytoplasmic/
membrane/nucleus expression. #2333T and #5999T showed high expression, #4465T and #403 showed reduced expression of p-EGFR.
Magnification of tissue samples is 20X, and for inset in tissues magnification is 40X. Scale bars in tissue sections represent 100 mm.
doi:10.1371/journal.pone.0063440.g004
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analyzed after siRNA transfection at 24 hour, 48 hour, 72 hour
and 96 hour. Maximum reduction in expression of the genes was
seen after 72 hour of siRNA treatment (data not shown). In
concordance with mRNA expression, protein expression of
SH3GL2 and CDC25A was significantly reduced after 72 hour
of siRNA treatment (Figure 5 c &d). Interestingly, EGFR and p-
EGFR expression were up regulated after knock down of either
SH3GL2 or CDC25A. Moreover, simultaneous knock down of
SH3GL2 and CDC25A resulted significant up regulation of both
EGFR and p-EGFR (Figure 5 c &d).
Association of HPV with Alterations of SH3GL2, CDC25A
and EGFR
Infection by HPV is considered as one of the important
etiological factors for HNSCC development. HPV typing was
done in this study to analyze the frequency of high-risk HPVs in
our samples. HPV DNA was detected in 52.2% (93/178) of the
tumors. Among the HPV positive samples, 92.5% (86/93) were
HPV-16-positive and 7.5% (7/93) were HPV-18 positive. HPV
infection was found to be significantly associated with tobacco
consumption (p = 0.0341) (Table 1).
Clinicopathological Correlation
Log rank test uncovered a statistically significant difference in
overall survival between cases with and without alterations in
CDC25A and SH3GL2 (p = 0.02). The patients having alterations
in both SH3GL2 and CDC25A had the worse overall survival
indicating prognostic significance of these genes among the
HNSCC patients (Figure 7a). In presence of HPV infection, the
patients having alterations in either or both CDC25A and SH3GL2
genes showed poor survival (p = 0.0461) (Figure 7b) whereas, no
such association has been seen in patients without HPV infection
(Figure 7c). Interestingly, worse prognosis of the patients have
Figure 5. SH3GL2 and CDC25A mediated EGFR homeostasis: a) EGFR was degraded due to upregulation of SH3GL2 and CDC25A by 5-aza-dc
treatment. Hep2 cell line was incubated with 20 mm of 5-aza-dc up to 120 h. Cells were harvested after zero hour of treatment and then every 24 h
interval. Equal amounts of protein were subjected to western blotting. The amount of EGFR protein decreased gradually and degradation was
maximum after 120 hour. Similarly, the expression of SH3GL2 and CDC25A was gradually increased after treatment. b) The amount of proteins
(normalized band OD) was plotted as a function of time of 5-aza-dc treatment. The intensity of the bands were determined by densitometry and
normalized with tubulin. c) SCC084 cell line was treated with siRNA of CDC25A and SH3GL2. Protein expression of the genes were analysed by
western blot. Expression of EGFR and phosphorylated EGFR were assayed during knock down either of SH3GL2 and CDC25A or of both. Both EGFR
and p-EGFR level was up regulated due to reduction of SH3GL2 and CDC25A. d) The amount of proteins (normalized band OD) was plotted. The
intensity of the bands were determined by densitometry and normalized with actin. The bar diagram showing the level of EGFR and p-EGFR up
regulation during siRNA treatment of SH3GL2 and CDC25A.
doi:10.1371/journal.pone.0063440.g005
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been seen with i) high EGFR protein expression and absence of
HPV infection (Figure 7d) and ii) with high EGFR and low
SH3GL2 protein expression in tumors (Figure 6e). On the
contrary, no significant differences in survival of patients were
observed having low or high protein expression of CDC25A and p-
EGFR (Figure 7f).
In univariate analysis alterations of SH3GL2, EGFR amplifica-
tion and absence of HPV infection showed hazardous to survival
of the patient (Table 4). Similarly, in multivariate analysis
alterations in SH3GL2 (p, 0.0305; HR, 1.69; CI, 1.0508–2.7212)
and EGFR amplification (p, 0.0036; HR, 1.905; CI, 1.234–2.938)
in absence of HPV infection (p, 0.04760; HR, 0.7182; CI, 0.4695–
1.098) were significant predictors for hazardous life and poor
survival of patients (Table 4).
Discussion
The aim of the study is to understand the molecular mechanism
of overexpression of EGFR protein in primary head and neck
lesions. EGFR was found to be overexpressed in majority (66–84%)
of dysplastic and HNSCC samples (Figure 2a) while, a low
frequency of amplification (26.4%) was observed in these samples
(Figure 2b). Low frequency of EGFR locus amplification (10–30%)
has also been reported in HNSCC [4]. In contrast to the mutation
in kinase domain of EGFR related to lung cancer, we did not find
any such mutations. Like our data, infrequent mutation of EGFR
has been reported in HNSCC [4]. However, mechanism of EGFR
overexpression in this tumor having absence of genetic alterations
in EGFR has not yet been elucidated. Although, a significant
correlation was seen between gene amplification and mRNA
expression, protein overexpression did not correlate with mRNA
expression status of EGFR (Table 2). Similar to our study, a low
frequency (,10%) of gene amplification and mutation have been
reported in different cancers including HNSCC in Cancer
Genome Project database [22]. This clearly suggests that
expression of EGFR is not regulated transcriptionally and
mechanism other than gene amplification/mutations might be
responsible for observed overexpression of this protein in HNSCC
tumors.
To understand the mechanism of EGFR protein overexpression
we analyzed alterations (deletion/methylation/mutation/expres-
sion) of SH3GL2 and CDC25A genes associated with EGFR
homeostasis. Frequent deletion/methylation of SH3GL2 (68%,
121/178) was evident in the head and neck lesions with
comparable frequencies (63% to 77%) in dysplastic lesions and
HNSCC samples (Figure S4) similar to that has been seen in our
earlier study [1]. This has been suggested to be associated with the
development of dysplastic lesions of this tumor. Frequent deletion
(31–38%) and promoter methylation (34–36%) of SH3GL2 has
been reported in breast and lung carcinoma [23,24] and also
deletion in pituitary adenoma, neuroblastoma and pilocytic
astrocytoma [25,26,27]. Similarly, in cancer genome project
Figure 6. Immunocytochemical analysis of EGFR, SH3GL2, CDC25A and p-EGFR. over night subconfluent cover slip culture of Hep2 cell line
was treated with 5-aza-dc for 72 hour and protein expression of the genes were analyzed by ICC after fixing the cells. EGFR and p-EGFR showed
reduced expression in treated cells (b) compare to non treated cells (a). On the contrary, SH3GL2 and CDC25A showed upregulation of cytoplasmic/
nuclear expression after aza treatment (b) compare to untreated cells (a). Scale bars in microphotograph represent 50 mm.
doi:10.1371/journal.pone.0063440.g006
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database, this gene has been reported to be inactivated by deletion
in wide variety of human cancer [28] in varying frequencies. The
alterations of SH3GL2 could lead to its reduced expression as
evident from the quantitative RT-PCR and IHC analysis. The
reduced expression of SH3GL2 was associated with alterations in
this gene (Table 2). Similar to our data, its reduced expression was
reported in HNSCC and carcinomas of breast and larynx
[1,10,23]. Infrequent mutation of SH3GL2 has been seen in the
samples except two novel SNPs (rs112820965 & rs201266191) in
the promoter region of this gene (Figure S2). The SNP
(rs201266191) overlaps with the transcription factor (GCF)
binding site and the minor allele (T) is prevalent in patients
suggesting its importance in this tumor development. However,
detailed study in this regard is warranted to understand the
importance of this SNP in expression of this gene. Interestingly,
alterations (deletion/promoter methylation) and reduced protein
expression of SH3GL2 showed significant association with EGFR
protein overexpression in the head and neck lesions (Table 2).
Moreover, the inverse expression pattern of these proteins in basal
layer of normal oral epithelium indicates that down regulation of
SH3GL2 is needed for overexpression of EGFR (Figure 2a,
Figure 4a).
SH3GL2 mediated EGFR degradation has been validated in
demethylation experiment by 5-aza-dc in Hep2 and siRNA
mediated knock down of SH3GL2 in SCC084 cell lines (Figure 5).
Increase in SH3GL2 mRNA expression after 5-aza-dc treatment
confirms the promoter methylation of the gene in Hep2 (Figure
S5). Similarly in kinetics analysis, gradual increase in SH3GL2
expression and gradual decrease in EGFR expression with
increasing time of 5-aza-dc treatment clearly suggest the associ-
ation of SH3GL2 with EGFR homeostasis as evident by western
blot analysis (Figure 5a &b). This was further confirmed by ICC
analysis after 5-aza-dc treatment where a decrease in EGFR
protein expression and increase in SH3GL2 expression were
Figure 7. Kaplan–Meier analysis of survival (up to 5 years) of HNSCC patients. a) Co-alteration of CDC25A and SH3GL2 was significantly
associated with poor overall survival (OS). b) The significant association with poor overall survival of patients having co-alterations of the genes was
also seen in presence of HPV infection; however, co-alterations did not associate significantly with OS in absence of HPV infection (c). d) Poor survival
was also seen of the patients having high EGFR expression irrespective of HPV infection. d) Similarly, reduced SH3GL2 expression and high EGFR
expression was a predictor for poor OS. However f), protein expression of p-EGFR and CDC25A did not show any significant association with survival
of the patients. Survival time was defined as the time from the date of surgery to the date of last follow-up, known recurrence or death (up to 5
years). n, total number of samples; C+/2, CDC25A deletion present/absent; S+/2, SH3GL2 alterations present/absent; H+/2, HPV infection present/
absent; EH/ML, EGFR protein expression high/medium to low; S-L/MH, SH3GL2 protein expression low/medium to high; C-H/ML, CDC25A protein
expression high/medium to low; p-EH/LM, p-EGFR protein expression high/low to medium.
doi:10.1371/journal.pone.0063440.g007
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markedly visualized (Figure 6). The association of SH3GL2 and
EGFR was also confirmed by siRNA mediated knock down of
SH3GL2 in SCC084 cell line (Figure 5c &d). The upregulation of
EGFR, as seen in our study, has also been reported by Shang et al
in Hep2 cell line [29]. Similarly, Dasgupta et al reported that
upregulation of SH3GL2 expression could induce EGFR protein
internalization and degradation in lung cancer cell lines [24]. This
suggests that inactivation of SH3GL2 might impair EGFR
endocytosis for degradation resulting its stabilization in HNSCC.
To find out the association of CDC25A with EGFR phosphor-
ylation in HNSCC, molecular alterations (deletion/methylation/
expression) of CDC25A and expression of p-EGFR were done in
same set of the head and neck lesions. Frequent deletion of
CDC25A was seen in dysplastic lesions and subsequent stages as
seen our previous report (Figure 4b, f) [14]. Deletion of CDC25A
has also been reported (cancer genome project database) in
varying frequencies in numerous human cancer [30]. Also, high
frequency of reduced expression (RNA/protein) of CDC25A was
seen in HNSCC samples as seen in our earlier study [14].
Differential expression (RNA/protein) pattern of CDC25A (30–
80%) has been reported in different carcinomas in liver,
esophagus, colon, breast including head and neck [31]. But none
has analyzed the alterations (deletion/methylation/mutation) of
this gene in these tumors. Though no methylation of CDC25A was
observed in our samples, the upregulation of this gene by 5-aza-dc
in Hep2 cell line suggests the presence of methylation in the some
other regulatory regions (Figure 5 & Figure 6). Further study in
this regard is needed to identify the regulatory regions of this gene.
The significant association of reduced CDC25A expression with
overexpression of p-EGFR in this tumor suggests their synergistic
action in development of tumor (Table 2). This was validated in
Hep2 cell line after 5-aza-dc treatment where upregulation of
CDC25A and down regulation of p-EGFR were evident (Figure 6).
On the other hand, EGFR/p-EGFR level was upregulated due to
knock down CDC25A by siRNA treatment (Figure 5 c & d).
Similarly, the inverse expression pattern of p-EGFR and CDC25A
was evident in the basal layer of normal oral epithelium (Figure 4b,
c). To the best of our knowledge, this is the first report of
regulation of EGFR phosphorylation by CDC25A in head and
neck lesions.
The worse prognosis of the patients having low SH3GL2 and
high EGFR expression (Figure 7e) suggests their prognostic
importance. Similarly, co-alterations of SH3GL2 and CDC25A in
tumors could also be used as prognostic marker for poor outcome
of patients (Figure 7a). Similar trend has also been seen in HPV
infected patients (Figure 7b). It was evident that HPV viral
oncoprotein E5 (expressed from episomal form of the virus) could
inhibit the EGFR endocytosis by disrupting the c-Cbl–EGFR
interaction [32]. But in invasive tumor, HPV is mainly in
integrated form with loss of E5 expression. Thus, association
between HPV and EGFR expression in invasive tumor, if any,
should be analyzed in detail. On the other hand, hazardous life
was predicted for the patients having EGFR amplification,
alterations of SH3GL2 and absence of HPV infection in tumors
(Table 4).
Thus, overexpression of EGFR/p-EGFR is due to impairment of
its homeostasis mechanism in HNSCC. The detailed analysis of
EGFR homeostasis pathway in HNSCC is warranted to develop
proper therapeutic measure of the tumor.
Supporting Information
Figure S1 Molecular alterations of EGFR.
(TIF)
Figure S2 Molecular alterations of SH3GL2.
(TIF)
Figure S3 ICC analysis of EGFR, p-EGFR, SH3GL2 and
CDC25A in presence and absence of 5-aza-dc.
(TIF)
Figure S4 Alterations(deletion/methylation) pattern of
SH3GL2 and CDC25A in dysplasia and HNSCC samples.
(TIF)
Figure S5 Demethylation experiment of SH3GL2 and
CDC25A in Hep2 cell line.
(TIF)
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Table S4 Correlation between DPCR and QPCR.
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Table S5 Molecular alterations of EGFR.
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Table S6 Association of alterations of genes with
different clinicopathological parametres.
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Table S7 Compilation of mutation analysis of SH3GL2.
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Table 4. Univariate and Multivariate analyses of genetic,
clinical, and etiological parameters in predicting overall
survival (OS) of 148 HNSCC patients.
Univariate Over all survival
Variable p value HR 95% CI for HR
SH3GL2 0.0288 1.6601 1.0539–2.61
CDC25A 0.502 1.1546 0.7589–1.7567
EGFR amp+ 0.0006 2.0799 1.366–3.166
HPV+ 0.035 0.6491 0.4336–0.9716
Grade .2104 0.8002 0.5645–1.1342
Stage .8976 0.9861 0.7970 1.2201
Node+ .6278 0.8940 0.5683 1.4063
Tobacco+ .5532 1.1530 0.7203 1.8456
Multivariate
SH3GL2 0.0305 1.6910 1.0508–2.7212
CDC25A 0.5015 1.1622 0.7497–1.8016
EGFR amp+ 0.0036 1.9050 1.2349–2.9386
HPV+ 0.0476 0.7182 0.4695–1.0985
Grade 0.2510 0.8105 0.5662–1.1602
Stage 0.8349 1.0265 0.8025–1.3131
Node+ 0.8289 0.9443 0.5616–1.5877
Tobacco+ 0.7770 1.0746 0.6533–1.7677
Amp+, Gene amplification present.
doi:10.1371/journal.pone.0063440.t004
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